Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 10, 2011, Pages 2164-2175

  Feng, Dan Dan ^a   Zhang, Hua ^a   Zhang, Peng ^b   Zheng, Yu Sheng ^a   Zhang, Xing Ju ^a   Han, Bo Wei ^a   Luo, Xue Qun ^c   Xu, Ling ^d   Zhou, Hui ^a   Qu, Liang Hu ^a   Chen, Yue Qin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Drug resistance; Leukaemia; MiR 27a; MiR 331 5p; P glycoprotein; Relapse

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; GLYCOPROTEIN P; MICRORNA; MIRN27 MICRORNA, HUMAN; MIRN331 MICRORNA, HUMAN;

ARTICLE; CELL STRAIN K 562; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LEUKEMIA; MALE; METABOLISM; PROTEIN SYNTHESIS; RECURRENT DISEASE; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; K562 CELLS; LEUKEMIA; MALE; MICRORNAS; P-GLYCOPROTEIN; PROTEIN BIOSYNTHESIS; RECURRENCE;

EID: 80053257151     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01213.x     Document Type: Article

References (41)

1. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997; 90: 2723-9.
2. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007; 67: 2456-68.
3. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006; 94: 1087-92.
4. Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics. 2006; 172: 2557-66.
5. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumours: current views and new therapeutic prospective. J Cell Physiol. 2006; 207: 571-81.
6. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993; 81: 2394-8.
7. Ivy SP, Olshefski RS, Taylor BJ, et al. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood. 1996; 88: 309-18.
8. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003; 8: 411-24.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
10. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 2007; 10: 59-67.
11. Sevignani C, Calin GA, Siracusa LD, et al. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006; 17: 189-202.
12. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68: 425-33.
13. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008; 123: 372-9.
14. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008; 7: 2152-9.
15. Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010; 79: 817-24.
16. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008; 76: 582-8.
17. Davies GF, Juurlink BH, Harkness TA. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther. 2009; 3: 79-88.
18. Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008; 6: e253.
19. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature. 2005; 434: 338-45.
20. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998; 95: 14863-8.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25: 402-8.
22. Grandjean F, Bremaud L, Verdier M, et al. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Anticancer Drugs. 2001; 12: 247-58.
23. Baran Y, Gur B, Kaya P, et al. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007; 12: 511-7.
24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20.
25. Yoon S, De Micheli G. Computational identification of microRNAs and their targets. Birth Defects Res C Embryo Today. 2006; 78: 118-28.
26. List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996; 10: 937-42.
27. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am. 1995; 9: 363-82.
28. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323-9.
29. McGrogan BT, Gilmartin B, Carney DN, et al Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008; 1785: 96-132.
30. Stewart J, Gorman NT. Multi-drug resistance genes in the management of neoplastic disease. J Vet Intern Med. 1991; 5: 239-47.
31. Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009; 45: 2197-206.
32. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med. 2007; 85: 923-35.
33. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999; 94: 1086-99.
34. Mertens-Talcott SU, Chintharlapalli S, Li X, et al The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007; 67: 11001-11.
35. Chintharlapalli S, Papineni S, Abdelrahim M, et al. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3, 11-dioxo-18beta-olean-1, 12-dien-30-oate in colon cancer cells. Int J Cancer. 2009; 125: 1965-74.
36. Zanette DL, Rivadavia F, Molfetta GA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007; 40: 1435-40.
37. Zhao X, Yang L, Hu J, et al miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res. 2010; 34: 1078-82.
38. Zhang H, Luo XQ, Zhang P, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009; 4: e7826.
39. Gallardo E, Navarro A, Vinolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30: 1903-9.
40. Navarro A, Diaz T, Martinez A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009; 114: 2945-51.
41. Spahn M, Kneitz S, Scholz CJ, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010; 127: 394-403.